What's in Groupe Oncologie Radiotherapie Tete et Cou's pipeline?

Groupe Oncologie Radiotherapie Tete et Cou has 9 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 3 in Phase 2, 1 in Phase 1.

Which companies overlap with Groupe Oncologie Radiotherapie Tete et Cou's portfolio?

Top competitors by shared drug class: AstraZeneca, Sun Yat-sen University, Eli Lilly and Company, Associazione Volontari Pazienti Oncologici, CatalYm GmbH.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/groupe-oncologie-radiotherapie-tete-et-cou.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Groupe Oncologie Radiotherapie Tete et Cou — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Groupe Oncologie Radiotherapie Tete et Cou pipeline: 2 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 3 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ethyol	Ethyol	marketed			Other
5-Fluorouracile	5-Fluorouracile	marketed	Antimetabolite; pyrimidine analog	Thymidylate synthase; RNA and DNA incorporation	Oncology
Ligufalimab	Ligufalimab	phase 3			Other
Carboplatin, 5FU concomitant	Carboplatin, 5FU concomitant	phase 3	Chemotherapy combination (platinum agent + antimetabolite)	DNA (carboplatin); thymidylate synthase (5FU)	Oncology
concomitant cisplatin	concomitant cisplatin	phase 3	Platinum-based chemotherapy	DNA	Oncology

Therapeutic area mix

Oncology · 4
Other · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Associazione Volontari Pazienti Oncologici · 1 shared drug class
CatalYm GmbH · 1 shared drug class
Central European Cooperative Oncology Group · 1 shared drug class
Barts & The London NHS Trust · 1 shared drug class
Centre Leon Berard · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Groupe Oncologie Radiotherapie Tete et Cou:

Cite this brief

Drug Landscape (2026). Groupe Oncologie Radiotherapie Tete et Cou — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/groupe-oncologie-radiotherapie-tete-et-cou. Accessed 2026-05-18.